These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28260416)

  • 1. Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Sormani MP
    Mult Scler; 2017 Mar; 23(3):378-381. PubMed ID: 28260416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: clinical aspects.
    Oh J; Vidal-Jordana A; Montalban X
    Curr Opin Neurol; 2018 Dec; 31(6):752-759. PubMed ID: 30300239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of treatment response in multiple sclerosis.
    Buck D; Hemmer B
    Expert Rev Neurother; 2014 Feb; 14(2):165-72. PubMed ID: 24386967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of biomarkers in multiple sclerosis.
    Bielekova B; Martin R
    Brain; 2004 Jul; 127(Pt 7):1463-78. PubMed ID: 15180926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
    Hegen H; Bsteh G; Berger T
    Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing Biomarkers for MS.
    Gnanapavan S; Giovannoni G
    Curr Top Behav Neurosci; 2015; 26():179-94. PubMed ID: 25502545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: use of MRI in evaluating new therapies.
    Miller DH
    Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials in multiple sclerosis.
    Cutter G; Kappos L
    Handb Clin Neurol; 2014; 122():445-53. PubMed ID: 24507530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized medicine in multiple sclerosis: hope or reality?
    Derfuss T
    BMC Med; 2012 Oct; 10():116. PubMed ID: 23035757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and prognosis of multiple sclerosis.
    Hassan-Smith G; Douglas MR
    Br J Hosp Med (Lond); 2011 Nov; 72(11):M174-6. PubMed ID: 22082979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body fluid biomarkers for multiple sclerosis--the long road to clinical application.
    Teunissen CE; Malekzadeh A; Leurs C; Bridel C; Killestein J
    Nat Rev Neurol; 2015 Oct; 11(10):585-96. PubMed ID: 26392381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate markers for time-varying treatments and outcomes.
    Hsu JY; Kennedy EH; Roy JA; Stephens-Shields AJ; Small DS; Joffe MM
    Clin Trials; 2015 Aug; 12(4):309-16. PubMed ID: 25948621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian hierarchical surrogate outcome model for multiple sclerosis.
    Pozzi L; Schmidli H; Ohlssen DI
    Pharm Stat; 2016 Jul; 15(4):341-8. PubMed ID: 27061897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating the tools for an individualized prognosis in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2013 Aug; 331(1-2):10-3. PubMed ID: 23692966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of multiple sclerosis: long-term prognostic factors.
    Renoux C
    Neurol Clin; 2011 May; 29(2):293-308. PubMed ID: 21439442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.